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Skin substitutes are of great beneﬁt in the treatment of patients with full thickness wounds, but there is a
need for improvement with respect to wound closure with minimal contraction, early vascularisation,
and elastin formation. In this study we designed and developed an acellular double-layered skin con-
struct, using matrix molecules and growth factors to target speciﬁc biological processes. The epidermal
layer was prepared using type I collagen, heparin and ﬁbroblast growth factor 7 (FGF7), while the porous
dermal layer was prepared using type I collagen, solubilised elastin, dermatan sulfate, heparin, ﬁbroblast
growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF). The construct was biochemically
and morphologically characterised and evaluated in vivo using a rat full thickness wound model. The
results were compared with the commercial skin substitute IntegraDRT and untreated wounds. The dou-
ble-layered construct was prepared according to the design speciﬁcations. The epidermal layer was about
40 lm thick, containing 9% heparin and 0.2 lg FGF7 mg per layer, localised at the periphery. The dermal
layer was 2.5 mm thick, had rounded pores and contained 10% dermatan sulfate + heparin, and 0.7 lg
FGF2 + VEGF mg per layer. The double-layered skin construct was implanted in a skin defect and on
day 7, 14, 28 and 112 the (remaining) wound area was photographed, excised and (immuno) histologi-
cally evaluated. The double-layered skin construct showed more cell inﬂux, signiﬁcantly less contraction
and increased blood vessel formation at early time points in comparison with IntegraDRT and/or the
untreated wound. On day 14 the double-layered skin construct also had the fewest myoﬁbroblasts pres-
ent. On day 112 the double-layered skin construct contained more elastic ﬁbres than IntegraDRT and the
untreated wound. Structures resembling hair follicles and sebaceous glands were found in the double-
layered skin construct and the untreated wound, but hardly any were found in IntegraDRT. The results
provide new opportunities for the application of acellular skin constructs in the treatment of surgical
wounds.
 2010 Acta Materialia Inc. Published by Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Skin substitutes are of major importance to patients whose bar-
rier function is compromised due to trauma, surgical wounds or
ulceration. The skin is the major organ involved in thermoregula-
tion and hydration, and acts as a barrier against infection [1].
Human full thickness defects larger than 4 cm in diameter will
not heal well without a graft [2]. Currently, autologous grafts pres-
ent the most effective treatment modality, but their availability is
limited, and the harvest of autologous skin creates new wounds atElsevier Ltd.
van Kuppevelt).
Open access under the Ethe donor site. Therefore, intensive research is being conducted on
the development of skin substitutes which can be used for imme-
diate wound closure, without the risk of infection, necrosis, tissue
hypertrophy, and contraction [3,4].
Several skin substitutes have been developed and tested in vivo.
A number of substitutes have obtained FDA approval and are avail-
able for clinical use, including Apligraf and IntegraDRT [2]. Apligraf
is a cell-based construct consisting of an epidermal layer of human
keratinocytes and a dermal layer composed of bovine type I collagen
and human ﬁbroblasts [5]. This construct is known to be a safe and
effective graft for use in chronic wounds. The cellularity of the con-
structs, however,makes it expensive to produce anddifﬁcult to han-
dle [6]. IntegraDRT is an acellular construct composed of a collagen–
chondroitin sulfate dermal layer and a silicon top layer. It is easy tolsevier OA license.
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ation, in which the dermal layer is ﬁrst allowed to become vascular-
ised [4]. In acellular constructs angiogenesis, graft take, and elastic
ﬁbre formation still need to be improved, whereas contraction
needs to be reduced [1,2]. In this study we address these issues
using a molecularly deﬁned construct, prepared from scratch.
Using a subcutaneous implantation model, we have previously
shown that a scaffold consisting of type I collagen supplemented
with glycosaminoglycans and ﬁbroblast growth factor 2 (FGF2) pro-
motes angiogenesis [7,8]. In addition, we showed that a scaffold
consisting of collagen and solubilised elastin enhances angiogenesis
and elastic ﬁbre formation [9,10], and that the combined addition of
two growth factors (FGF2 and vascular endothelial growth factor
(VEGF)) reduced the timespan to obtain vasculature from a period
of 3 weeks to7 days [11]. Fournier et al. also showed that FGF2 re-
quires additional components, like hyaluronic acid, to enhance its
angiogenic effect [12]. As well as its role in angiogenesis, FGF2
may also reduce wound contraction by inhibiting the phenotypic
change of ﬁbroblasts to myoﬁbroblasts, which is likely involved in
contraction [13–15]. Heparin is known to stimulate ﬁbroblasts to
produce FGF2 [16], inﬂuencing angiogenesis andmyoﬁbroblast for-
mation. In vitro TGF-b induces ﬁbroblast differentiation into myoﬁ-
broblasts [15]. Lammers et al. showed that the extent andmethod of
cross-linking inﬂuences the proliferation of keratinocytes [17].
Based on this knowledge, a double-layered skin construct was
designed and constructed containing speciﬁc factors to stimulate
important biological processes in skin regeneration (Fig. 1). The
construct consisted of two layers: a collagenous epidermal layer
containing heparin and FGF7 (which stimulates keratinocyte pro-
liferation) and a porous dermal layer consisting of type I collagen
ﬁbrils, solubilised elastin, dermatan sulfate, heparin, FGF2 and
VEGF. Both layers were chemically cross-linked using 1-ethyl-3-
dimethyl aminopropyl carbodiimide (EDC) and N-hydroxy-
succinimide (NHS). This molecularly deﬁned construct was
characterised and evaluated in vivo using a rat full thickness
wound model, suitable to evaluate skin constructs [18,19]. The
results were compared with commercial IntegraDRT and untreated
wounds.Fig. 1. Design and rationale of the double-layered skin construct, consisting of an
epidermal (ﬁlm) layer and a dermal (porous) layer. The epidermal layer contained
type I collagen, heparin and recombinant rat FGF7. The dermal layer consisted of
type I collagen, solubilised elastin, dermatan sulfate (DS), heparin and the
recombinant rat growth factors FGF2 and VEGF. The construct was designed to
resemble the architecture of normal skin and to contain speciﬁc effector molecules.
Heparin was added to the epidermal layer for hydration and growth factor binding,
and FGF7 to stimulate keratinocyte migration and proliferation. Solubilised elastin
was added to the dermal layer to induce elastic ﬁbre formation, DS and heparin to
provide hydration and growth factor binding, VEGF to promote angiogenesis and
FGF2 to enhance ﬁbroblast proliferation and angiogenesis and to decrease myoﬁ-
broblast formation.2. Materials and methods
2.1. Materials
Unless stated otherwise, all chemicals were purchased from
Merck Chemicals (Darmstadt, Germany). Type I collagen ﬁbrils
were puriﬁed from bovine achilles tendon as described [20]. Solu-
bilised elastin was prepared from equine ligamentum nuchae as
described [9]. Heparin and dermatan sulfate (DS) were purchased
from Sigma Chemical Co. (St. Louis, MO). Recombinant rat FGF2
was produced in Escherichia coli M15 PQE16 [8] and recombinant
rat VEGF-164 in Pichia pastoris GS115 [21]. Recombinant rat FGF7
was purchased from QED Biosciences (San Diego, CA). IntegraDRT
(Integra dermal regeneration template) was purchased from Inte-
gra Lifesciences Corporation (Plainsboro, NY). Antibodies against
bovine type I collagen, bovine elastin (cross-reacting with equine
elastin), rat VEGF, rat elastin, rat type I collagen, rat type III colla-
gen, bovine FGF2, human type IV collagen and a-smooth muscle
actin (the last three cross-reacting with rat epitopes) were pur-
chased and diluted as described [9,11]. Single chain variable frag-
ment antibodies against heparin (antibody HS4C3 [22]), DS
(antibody GD3A12 [23]) and chondroitin sulfate (CS) (antibody
IO3H10 [24]) were prepared as described. Goat anti-human FGF7
(cross-reacting with rat FGF7) was purchased from R&D Systems
(Minneapolis, MN).2.2. Preparation of the double-layered skin construct
The double-layered skin construct consisted of a dermal and
epidermal layer. The dermal layer was prepared by freezing a sus-
pension containing 0.64% (w/v) type I collagen and 0.16% (w/v) sol-
ubilised elastin in 0.25 M acetic acid at 20 C [9,25], followed by
lyophilisation using a Zirbus lyophiliser (Bad Grund, Germany).
The resulting scaffold was chemically cross-linked with 33 mM
EDC and 6 mM NHS in the presence of 0.375% (w/v) DS and
0.125% (w/v) heparin for 4 h in 50 mM 2-morpholinoethane sul-
fonic acid (pH 5.0) containing 40% ethanol, and washed with
0.1 M Na2HPO4, 1 M NaCl, 2 M NaCl and demineralised water [9].
Growth factors were bound to the dermal layer by incubation
(1 ml per 8 mg scaffold) in 3.5 lg ml1 FGF2 and 3.5 lg ml1 VEGF
in phosphate-buffered saline (PBS), pH 7.4, for 60 min, followed by
5  15 min washes with PBS.
The epidermal layer was produced by air drying a 0.8% type I
collagen suspension in 0.25 M acetic acid [17], followed by EDC/
NHS cross-linking in the presence of 0.5% heparin as described
above. The epidermal layer (1 ml solution per 20 mg scaffold)
was incubated in 0.5 lg ml1 FGF7 in PBS, followed by
5  15 min washes with PBS.
The wet dermal and epidermal layers were glued to each other
using a 0.5% collagen suspension in 0.25 M acetic acid. The total
construct was quickly frozen at 80 C and lyophilised.2.3. Characterisation of the construct
A number of morphological and biochemical techniques was
applied to characterise the double-layered skin construct and com-
mercial IntegraDRT.
The ultrastructure of the constructs was analysed using scan-
ning electron microscopy (SEM) [11].
The extent of cross-linking was estimated by determination of
the number of amine groups, which was analysed using 2,4,6-trini-
trobenzene sulfonic acid [26].
The glycosaminoglycan contents (dermatan sulfate, chondroitin
sulfate and heparin) of the epidermal layer, dermal layer and
IntegraDRT were determined by a hexosamine assay using
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for heparin and chondroitin sulfate/dermatan sulfate had different
slopes, two calibration curves were used. The total glycosaminogly-
can content of the dermal layer was calculated by adding the num-
bers obtained for dermatan sulfate and heparin (in a 3:1 ratio).
The amount of growth factor bound to the epidermal and der-
mal layer was determined by Western blotting [27] using antibod-
ies against FGF2 (1:2000), VEGF (1:1000) and FGF7 (1:400). Bound
antibodies were visualised using peroxidase-conjugated secondary
antibodies and a chemiluminescent detection kit (ECL, Amersham
Biosciences) and analysed with Gene Tools software (Syngene,
Cambridge, UK). The calibration curves ranged from 0 to 100 ng
growth factor. Scaffolds without growth factors were used as
controls.
The distributions of type I collagen, elastin, dermatan sulfate,
chondroitin sulfate, heparin, FGF7, FGF2 and VEGF were deter-
mined by immunoﬂuorescence assay using speciﬁc antibodies as
described [9,11]. For DS and CS the secondary antibody was mouse
anti-VSV tag (1:5) [22] and the tertiary antibody goat anti-mouse
IgG Alexa488 (1:200). For FGF7 the secondary antibody was rabbit
anti-goat IgG Alexa488 (1:200). Omission of the primary antibody
was taken as a negative control.
2.4. Implantation of the construct
NIH guidelines for the care and use of laboratory animals (NIH
publication 85–23 Rev. 1985) were observed. The study was ap-
proved by the Ethics Committee of the Radboud University Nijme-
gen. Wistar rats (male, 3 months old) were purchased from Harlan
(Horst, The Netherlands). The rats were housed separately and fed
pelleted diet (RMH-B 10 mm) and water ad libitum. The rats were
anesthetised with isoﬂurane.
7 days prior to the operation the wound area was marked intra-
dermally with eight dots of tattoo ink (Hauptner, Germany). Before
surgery analgesia (injection with midazolam, morphine and car-
profen) was given. Post-operative analgesia was also given (injec-
tions of carprofen twice a day for 2 days). The constructs
(1.5  1.5 cm) were disinfected in 70% ethanol (3  30 min and
one overnight incubation) and washed with sterile PBS
(6  60 min). Two full thickness wounds of 1.5  1.5 cm, including
the panniculus carnosus, were made on each side of the back of the
rat and the constructs were placed in the wounds. The wounds
were treated either with the double-layered skin construct,
IntegraDRT or left untreated. The double-layered skin construct
and IntegraDRT were placed in the wound in such a way that they
ﬁtted exactly and touched the wound edge, without overlap with
the wound edge. The constructs were kept in place by four resorb-
able sutures (5–0 Vicryl). The wounds were dressed with gauze,
Tensoplast and Leukoplast. The bandage was applied for 14 days.
Each individual rat received two different treatments (double-
layered skin construct and/or IntegraDRT and/or no treatment).
Each treatment was applied four times for each time point, result-
ing in a total of six rats per time point. After 14 days the silicon
layer of IntegraDRT was removed. On days 7, 14, 28 and 112 the
rats were killed and the implants and surrounding tissues were
removed. The explants were divided in several parts and processed
for conventional histology and immunohistochemistry.
2.5. Analysis of contraction
On days 7, 14, 28 and 112 wound contraction was evaluated by
determination of the remaining wound area using photographs
and a ruler at each time point (n = 4). Day 0 was taken as 100%
(no wound contraction). Results are presented as means ± SD.
The effect of the different treatments on the size of the wound area
was analysed by factorial analysis of variance (ANOVA) followed bya post hoc test (Duncan’s multiple range test) using the Statistica
software package (StatSoft, Tulsa, OK).2.6. Processing of explants
2.6.1. Histology
Parafﬁn sections were cut and stained with haematoxylin and
eosin (HE), Elastin von Gieson (EVG) [28] and Verhoeff’s elastic tis-
sue–Masson’s trichrome stain [29]. Phase contrast microscopy was
used to study the location and direction of newly-formed collagen
ﬁbres. Histology of the explants was evaluated independently by at
least two experienced investigators. Sections were scored using a
scale of  (not present) to +++ (abundant).2.6.2. Immunostaining
To study construct degradation, extracellular matrix formation,
the presence of blood vessels and number of myoﬁbroblasts cryo-
sections were stained with speciﬁc antibodies. Antibodies against
bovine type I collagen, bovine elastin, heparin, dermatan sulfate
and chondroitin sulfate were used to evaluate the (remains of)
the construct. No major cross-reactivity was found between bovine
and rat collagen or between bovine and rat elastin, and in combi-
nation with the size and the position of the collagen ﬁbres and
elastin material, the differences between the two species could
be easily distinguished. Antibodies against rat type I and type III
collagen were used to analyse the presence of rat collagen, an anti-
body against rat elastin to visualise elastin formation and an anti-
body against dermatan sulfate to evaluate glycosaminoglycan
production. An anti-type IV collagen antibody was used to visualise
blood vessels and an anti-smooth muscle actin (SMA) antibody to
analyse the presence of myoﬁbroblasts and the maturity of blood
vessels. Sections were scored using a scale ranging from  (not
present) to +++ (abundant).3. Results
3.1. Characterisation of the constructs
3.1.1. Double-layered skin construct
The morphology of the construct was analysed using SEM
(Fig. 2A–D). The epidermal top layer was a thin non-porous colla-
gen layer with a thickness of 40 lm (Fig. 2A and C, Table 1).
The dermal layer was approximately 2.5 mm thick with rounded
pores of generally 75–125 lm diameter (Fig. 2A and D, Table 1).
The glue layer of collagen had a thickness of 25–30 lm and con-
tained pores of 10 lm diameter (Fig. 2B).
The layers were individually cross-linked with EDC/NHS to
covalently bind the glycosaminoglycans (94 lg heparin mg per
epidermal layer, 103 lg dermatan sulfate + heparin mg per dermal
layer) (Table 1). In the cross-linking process about 50% of the free
amine groups were used (Table 1). The amount of growth factor
bound to each layer (0.2 lg FGF7 mg per epidermal layer and
0.7 lg FGF2 + VEGF mg per dermal layer) was determined by
Western blotting and using Gene Tools (Table 1).
The distribution of all components in the construct was visual-
ised using immunostaining (Fig. 2E–L), and was in accordance with
the original design (Fig. 1). Both the epidermal and dermal layers
contained type I collagen, whereas solubilised elastin was only
present in the dermal layer. Heparin was distributed throughout
the whole construct, with more intense staining of heparin in the
epidermal layer. Dermatan sulfate, FGF2 and VEGF were found dis-
tributed throughout the dermal layer, the growth factors showing
a more intense staining at the epidermal side. FGF7 was only pres-
ent at the periphery of the epidermal layer.
Fig. 2. Electron microscopical and immunological evaluation of the double-layered skin construct and IntegraDRT. (A–D) Scanning electron micrographs of the double-
layered skin construct: (A) cross-section, the arrow indicates the epidermal layer; (B) the glue layer, indicated by a double-headed arrow; (C) the top of epidermal layer; (D)
the dermal layer. (E–L) Immunolocalisation of (E) type I collagen, (F) heparin, (G) FGF7, (H) negative control, (I) elastin, (J) dermatan sulfate, (K) FGF2 and (L) VEGF. The
epidermal (top) layer is indicated by a dashed line. (M–P) Scanning electron micrographs of IntegraDRT: (M) cross-section; (N) close-up of (M); (O) top of the silicon layer; (P)
top of the dermal layer. In (M) and (N) # indicates the silicon layer and * the dermal collagen layer. Bar = 100 lm in (A), (D–N) and (P); 10 lm in (B) and (C); 1 lm in (O).
Table 1
Pore size and biochemical properties of the implanted constructs.
Pore size (lm) Amine group content (nmol/mg scaffold) Glycosaminoglycan content (lg/mg scaffold] Growth factor content (lg/mg scaffold)
Epidermal layer <1 132 ± 16 (56%) 94 ± 10 (hep) 0.2 ± 0.07 (FGF7)
Dermal layer 75–125 154 ± 11 (48%) 103 ± 118 (DS/hep) 0.7 ± 0.3 (FGF2/VEGF)
IntegraDRTa 50–100 164 ± 35 24 ± 4 (CS) –
Pore size and biochemical analysis of the epidermal layer, dermal layer and IntegraDRT. The amine group content was determined using 2,4,6-trinitrobenzene sulfonic acid
[22], the percentage cross-linking in comparison with the non-cross-linked scaffold is displayed in parenthesis. The glycosaminoglycan (heparin, DS and CS) content was
determined using p-dimethyl-aminobenzoaldehyde [15]. Non-cross-linked collagen contained 298 ± 57 nmol amine groups mg scaffold1. The results are the means ± SD of
three independent experiments. Please note that no controls could be taken for the IntegraDRT construct.
a Measured without the silicon layer.
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SEM indicated that in commercial IntegraDRT the collagen part
was 750 lm thick with 50–100 lm pores and that the silicon
layer was 300 lm thick (Fig. 2M–P, Table 1). IntegraDRT is dehy-
drothermally cross-linked [30]. Analysis of the collagen layer indi-
cated that 1 mg contained about 164 nmol amine groups and about
24 lg chondroitin sulfate (Table 1, note that a control without
cross-linking or without chondroitin sulfate was not available).
Immunostaining was used to analyse the distribution of type I col-
lagen and CS and both were equally distributed throughout the col-
lagen layer (data not shown).3.2. Evaluation of the constructs in full thickness wounds
No infections or illnesses were observed in the rats and they
stayed healthy without considerable weight loss. Rats scratched
more on IntegraDRT-covered wounds with the silicon layer pres-
ent. Some rats even removed the layer, indicating that the silicon
layer caused irritation. Tattoo ink was used to mark the woundarea, but the dots were generally too large and too unequal in size
to use for an accurate determination of the remaining wound area.
The double-layered skin construct was constructed from two
layers, an epidermal ﬁlm layer and a porous dermal layer. The
two layers were attached to each other by a thin collagen ‘‘glue’’
layer, which ﬁrmly attached both layers in such a way that during
all procedures (e.g. disinfection and suturing) the construct stayed
intact and was easy to handle. During the experiment we noticed
that on days 7 and 14 the epidermal layer was still attached to
the dermal layer, but that at later time points the layer was loos-
ened by epidermal cells that tended to migrate between the two
layers.
On day 40 the wounds of all groups were closed (data not
shown).
3.2.1. Wound contraction
On day 7 a signiﬁcant difference in wound contraction was
found between the double-layered skin construct and the un-
treated wound (P < 0.05). The double-layered skin construct occu-
pied a larger area (90 ± 8% of the original wound area) in
Fig. 3. Degree of wound contraction as analysed by the remaining wound area. (A)
Macroscopical images of the wound area on days 0 and 14. (B) Quantitative data on
the remaining wound area. Values are means ± SD (n = 4). On day 7 a signiﬁcant
difference was found between the untreated wound versus the double-layered skin
construct (P < 0.05*). On day 14 the double-layered skin construct was found to
have signiﬁcantly less contraction than IntegraDRT and the untreated wound
(P < 0.008^ and P < 0.002#, respectively).
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occupied 84 ± 16% of the original wound area (Fig. 3B).
On day 14 the double-layered skin construct showed signiﬁ-
cantly less contraction than IntegraDRT and the untreated wound
(P < 0.008 and P < 0.002, respectively). The double-layered skin
construct (80 ± 16%) occupied a larger area than IntegraDRT
(47 ± 19%) and the untreated wound (39 ± 22%) (Fig. 3A and B).
On days 28 and 112 the remaining wound areas for all treat-
ments ranged from 12–31% and no major differences were ob-
served between the groups.3.3. Microscopical evaluation
3.3.1. Cellular response
Table 2 presents a semi-quantitative analysis of cells present in
the wound area.
On day 7 little epidermis had formed in all three groups (data
not shown). The double-layered skin construct had the highestTable 2
Cellular response in the wound area after treatment, compared with normal s
Days after implantation Granulocytes
Double-layered 7 +++
skin construct 14 ++
28 +
112 
IntegraDRT 7 ++
14 +++
28 +
112 
Untreated wound 7 +
14 ++
28 ±
112 –
Normal skin –
The cells were scored from absent () to abundantly present (+++). The abso
* Phagocytic cells include macrophages and giant cells.
# The myoﬁbroblasts were visualised using an antibody against smooth mus
by 1moderate or 2abundant.number of granulocytes. The numbers of phagocytic cells and
ﬁbroblasts were equal for all three groups.
On day 14 partial coverage by epidermal tissue was observed in
all three groups. The double-layered skin construct and the un-
treated wound showed some granulocytes, whereas larger num-
bers were observed in IntegraDRT. No differences were observed
with respect to macrophages and ﬁbroblasts.
On day 28 all groups showed further coverage, but complete
wound closure was not yet seen. Keratinocytes had generally mi-
grated under the epidermal layer of the double-layered skin con-
struct, resulting in release of the dense layer of the construct (as
a scab). The double-layered skin construct and IntegraDRT con-
tained more granulocytes and phagocytic cells than the untreated
wound. No differences in number of ﬁbroblasts were found be-
tween the three groups.
On day 112 all three groups had a fully developed epidermis,
but no rete ridge structures were present in the newly formed epi-
dermis. The thickness of the epidermis (measured as the number of
cell layers) was found to be variable within each group, but no ma-
jor differences were observed. Granulocytes were absent. Com-
pared with normal skin, slightly more macrophages appeared to
be present in the healed area of all three groups (Table 2 and
Fig. 4A). Structures resembling hair follicles and sebaceous glands
were observed in the double-layered skin construct and the un-
treated wound, but hardly any were found in IntegraDRT. Most
of these structures were located in the vicinity of the wound edges
in the newly formed matrix (Fig. 4B and C).
None of the groups showed newly formed skeletal muscle tissue
(replacing the excised panniculus carnosus) at any time point
examined.
3.3.2. Myoﬁbroblasts
On day 7 the overall score for myoﬁbroblasts was comparable
between the treatments (Table 2). The double-layered skin con-
struct had more myoﬁbroblasts present than IntegraDRT and the
untreated wound only at the wound edges. On day 14, however,
the double-layered skin construct overall contained fewer myoﬁ-
broblasts than IntegraDRT and the untreated wound. On day 28
the untreated wound showed the fewest myoﬁbroblasts. In gen-
eral, more myoﬁbroblasts were observed at the wound edges than
in the middle of the wound area. No myoﬁbroblasts were observed
on day 112 and in normal skin.
3.3.3. Construct components
3.3.3.1. Collagen. Immunostaining for construct type I collagen
showed that on day 7 most of the material of the double-layeredkin.
Phagocytic cells* Fibroblasts Myoﬁbroblasts#
++ ++ +2
++ ++ +1
++ ++ ++2
+ ++ 
++ ++ +1
++ ++ ++2
++ ++ ++1
+ ++ 
++ ++ +1
++ ++ ++2
+ ++ +
+ ++ –
± ++ 
lute numbers of granulocytes are much lower than for phagocytic cells.
cle actin. More myoﬁbroblasts were found at the wound edges, indicated
Fig. 4. Histological images of the centre of the wound area on day 112. (A) Haematoxylin and eosin (HE) staining, (B) elastic Masson’s staining (EM and (C) phase contrast
(PH) images of the double-layered skin construct, IntegraDRT and untreated wound compared with normal skin. (A) A closed epidermis was present in all cases and no
differences were found in the number of cell layers. Rete ridge structures were absent. The dermis of the double-layered skin construct, IntegraDRT and the untreated wound
showed higher numbers of cells than the normal skin (nuclei of the cells stained in blue). (B) In the double-layered skin construct and the untreated wound hair follicle-like
and gland-like structures (arrows) were observed (also visible in (C)). Mature collagen ﬁbres stained red, whereas the newly formed ﬁbres are light blue. (C) Phase contrast
microscopy revealed that collagen ﬁbres were more randomly oriented in the double-layered skin construct and untreated wound than in IntegraDRT. The bar in (A) is 25 lm,
in (B) and (C) 100 lm.
Table 3
Overview of immunostaining for matrix molecules in the wound area after treatment, compared with normal skin.
Days after implantation Construct Newly-formed matrix components
Type I collagen Elastin Type I collagen Type III collagen Elastin Dermatan sulfate
Double-layered 7 ++ + + ++ ± ++
skin construct 14 + + ++ ++ + ++
28 ± – ++ ++ + +++
112   +++ ++ +++ ++
IntegraDRT 7 ++  ± +  +
14 +  + ++ ± +
28 ±  ++ ++ ± +
112   +++ ++ ++ ++
Untreated wound 7   + + + ++
14   ++ ++ + ++
28   +++ ++ ++ ++
112   +++ ++ ++ +++
Normal skin   +++ + ++ +++
The sections were scored from absent () to abundantly present (+++).
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14 collagen remnants were found in both the double-layered skin
construct and in IntegraDRT, whereas on day 28 only a few colla-
gen remnants were observed. On day 112 no scaffold collagen
could be observed.
3.3.3.2. Elastin. On days 7 and 14 the elastin staining of the double-
layered skin construct showed small fragments, indicating degra-
dation of the scaffold elastin. No scaffold bound elastin staining
was seen on days 28 and 112.
3.3.3.3. Glycosaminoglycans. On days 7 and 14 heparin was mainly
visible in the epidermal layer of the double-layered skin construct,
whereas dermatan sulfate was only found on the collagen ﬁbrils of
the dermal layer (data not shown). On day 28 hardly any stainingwas observed of construct glycosaminoglycan remnants. Integra-
DRT showed staining for chondroitin sulfate on the collagen ﬁbrils
on days 7 and 14.
3.3.4. Newly formed extracellular matrix components
The presence of rat extracellular matrix components is summa-
rized in Table 3. Using immunostaining it was shown that normal
skin contained randomly oriented type I collagen ﬁbres, a small
amount of type III collagen, a moderate number of elastic ﬁbres
at the top of the dermal layer and ample amounts of DS scattered
throughout the dermis.
3.3.4.1. Type I collagen. The amount of rat type I collagen increased
with time, being abundant in all three groups on day 112. On days
7 and 14 the double-layered skin construct and the untreated
S.T.M. Nillesen et al. / Acta Biomaterialia 7 (2011) 1063–1071 1069wound contained more type I collagen than IntegraDRT, whereas
on day 28 the untreated wound contained most type I collagen.
Phase contrast microscopy was used to analyse the location and
orientation of newly-formed collagen bundles on day 112. The
double-layered skin construct and the untreated wound had a
more randomly oriented collagen deposition, whereas the collagen
bundles in IntegraDRT were found to be more aligned (Fig. 4C).
When comparing the results of the treatments with normal skin,
the double-layered skin construct and the untreated wound resem-
bled normal skin on day 112 more closely than IntegraDRT.
3.3.4.2. Type III collagen. On day 7 the double-layered skin con-
struct contained a moderate amount of rat type III collagen,
whereas IntegraDRT and the untreated wound contained less.
From day 14 on a moderate amount was found in all three groups.
3.3.4.3. Elastin. The number of elastic ﬁbres increased with time,
being most abundant in the double-layered skin construct on day
112 (Fig. 5). On days 7, 14 and 28 IntegraDRT contained the fewest
elastic ﬁbres, while the untreated wound had the same or more
elastic ﬁbres than the double-layered skin construct.
On days 7, 14 and 28 the least dermatan sulfate was found in
IntegraDRT. On day 28 the double-layered skin construct contained
most dermatan sulfate, whereas on day 112 the untreated wound
contained most dermatan sulfate, a similar level to normal skin.
3.3.5. Blood vessels
On days 7 and 14 the double-layered skin construct and the un-
treated wound contained more blood vessels than IntegraDRT
(Fig. 6). Blood vessels had already invaded the double-layered skin
construct by day 7, whereas hardly any blood vessels were found
inside the collagen layer of IntegraDRT. On day 28 the double-lay-
ered skin construct still had many blood vessels present, whereas
the untreated wound and IntegraDRT contained a moderate num-
ber. The blood vessels were evenly distributed throughout the
wound area. On day 112 all groups had moderate numbers of blood
vessels present in the wound area. These were smaller but more
abundant than in normal skin.4. Discussion
In this study an acellular double-layered skin construct was
prepared from puriﬁed components, according to a predeﬁned de-
sign. The biological components and their location were chosen to
reﬂect the extracellular environment of the skin. Growth factors
were positioned in such a way as to locally exert their activity,Fig. 5. Immunohistochemical evaluation of newly formed elastin on day 112, analysed
around blood vessels and hair follicle-like structures and a large number of elastic ﬁbre
moderate number of elastic ﬁbres that were mainly located in the upper part of the de
structures. Normal skin showed elastic ﬁbres around blood vessels and hair follicles ine.g. FGF7 at the periphery of the ﬂat epidermal layer and FGF2
and VEGF throughout the porous dermal layer. The double-layered
skin construct was developed to accelerate and improve wound
healing. In clinic applications acellular constructs may be preferred
over cellular constructs for their ease of handling, transport and
storage.
The performance of the double-layered skin construct was com-
pared with IntegraDRT and an untreated wound (no skin con-
struct). The double-layered construct had signiﬁcantly less
contraction at the ﬁrst two time points (days 7 and 14) compared
with the untreated wound, and on day 14 compared with Integra-
DRT. At later points no signiﬁcant differences were found. The
number of smooth muscle actin-positive myoﬁbroblasts, likely in-
volved in wound contraction [14], was also least in the double-
layered construct on day 14. This suggests inhibition of the
differentiation of ﬁbroblasts to myoﬁbroblasts by the construct.
FGF2 is known to inhibit myoﬁbroblast formation and promote
the ﬁbroblast phenotype [31]. The FGF2 present in the double-
layered skin construct may have been instrumental in diminishing
the number of myoﬁbroblasts present on day 14. Fibroblasts are
involved in the production of extracellular matrix (for instance col-
lagens and elastin) and growth factors and play a crucial role in
regulating skin physiology [32]. Boehnke et al. described an equiv-
alent consisting of ﬁbroblasts in a three-dimensional scaffold. They
showed the importance of the interaction between ﬁbroblasts and
keratinocytes for the proliferation, regeneration and organogenesis
of a skin equivalent [33]. The double-layered skin construct con-
tained FGF2 to increase ﬁbroblast proliferation in order to enhance
wound repair and regeneration. However, no differences were
observed in the number of ﬁbroblasts in the wound, suggesting
that FGF2 was more involved in angiogenesis and inhibition of
myoﬁbroblast formation.
In addition, the random orientation of the pores in the con-
struct may have prevented the remaining myoﬁbroblasts from
contracting the wound area. When cells are randomly bound to
the scaffold the sum of the contracting forces is near zero [34].
However, on day 28 more myoﬁbroblasts were found than on
day 14 in the double-layered skin construct. FGF2 has a short life-
span, which is increased by binding to heparin [35], but after
28 days most of the construct was degraded, and a lack of FGF2
may eventually have abolished active inhibition of differentiation
into myoﬁbroblasts. Fournier et al. determined that a ﬁbrin gel
with hyaluronic acid and FGF2 gave burst release in vivo [12]. A
more sustained release of FGF2 may reduce the degree of contrac-
tion for a longer period of time. A decrease in the mechanical
properties of the construct, due to degradation, may have added
to this effect.using an antibody for elastin. The double-layered skin construct showed elastin
s throughout the upper dermis. IntegraDRT and the untreated wound contained a
rmis. The untreated wound also showed elastic ﬁbres surrounding hair follicle-like
the dermis. Bar 25 lm.
Fig. 6. The presence of blood vessels in the wound area as visualised using an antibody against type IV collagen. The top of the dermis/epidermal layer is indicated by a
dashed line. In the double-layered skin construct and untreated wound more blood vessels were present on days 7 and 14, and they had penetrated further towards the
epidermis in comparison with IntegraDRT. On day 28 the double-layered skin construct possessed more blood vessels than IntegraDRT and the untreated wound. On day 112
all treatments showed a similar number of blood vessels, more abundant and with a smaller diameter compared with normal skin. Bar 100 lm.
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in increased early inﬁltration of cells [8,11]. Indeed, on day 7 the
double-layered skin construct showed more inﬂux of, for example,
granulocytes compared with IntegraDRT and the untreated wound
(however, on day 14 IntegraDRT showed more granulocyte inﬂux).
Inﬁltration of cells is necessary for good and rapid wound healing,
in order to boost the wound healing process. Cytokines produced
by the inﬁltrating cells promote angiogenesis, extracellular matrix
production and remodeling [36,37]. Currently used acellular scaf-
folds such as IntegraDRT lack growth factors, but our study sug-
gests that growth factors may be necessary to induce early
angiogenesis and extracellular matrix production.
Commercially available acellular skin substitutes require sev-
eral weeks to acquire a well-developed vasculature. This results
in impaired wound healing, due to a lack of oxygen and nutrients
and the presence of waste products [38]. Angiogenesis can be pro-
moted by the incorporation of glycosaminoglycans or solubilised
elastin into a scaffold, as previously shown in a subcutaneous
implantation model in the rat [8,9]. In addition, the combination
of two growth factors (FGF2 and VEGF) in an acellular collagen–
heparin scaffold had induced a mature vasculature already by
day 7 [11]. In the double-layered skin construct many bloodvessels were found on day 7, in contrast to IntegraDRT, which
did not develop a similar number of blood vessels at any of the
time points examined. Moiemen et al. found that IntegraDRT was
only fully vascularised after 4 weeks in humans [39]. This is in line
with our ﬁndings that it took until day 28 before the newly formed
vasculature in IntegraDRT had reached the top of the construct. The
addition of growth factors to an acellular construct may thus
greatly improve angiogenesis.
The orientation of collagen ﬁbres in normal skin has a basket
weave pattern, whereas in scars the ﬁbres are very much aligned
in parallel [40]. We and others have seen that the micro-architec-
ture of the original scaffold inﬂuences the orientation of newly-
formed collagen ﬁbrils [41,42]. In the double-layered skin con-
struct the dermal layer had large randomly oriented pores to allow
random collagen deposition, which indeed occurred, as indicated
by phase contrast microscopy.
An interesting feature was the presence of structures resem-
bling hair follicles and sebaceous glands in the double-layered skin
construct and untreated wound on day 112. These structures were
mainly found in the outer region of the healed wound, although
some were found in the center. Ito et al. demonstrated that in adult
mice de novo hair follicle formation was found after the excision of
S.T.M. Nillesen et al. / Acta Biomaterialia 7 (2011) 1063–1071 10711 cm2 full thickness back skin [43]. Growth factors (e.g. epidermal
growth factor and FGF) are involved in hair follicle and sebaceous
gland development [44]. Therefore, there is a possibility that some
of the hair follicles and glands observed were generated de novo,
although most of the structures were likely derived from adjacent
healthy tissue. Further research will establish whether the addition
of (a combination of) growth factors to an engineered skin con-
struct can indeed induce hair follicle formation.5. Conclusion
A double-layered skin construct was designed, developed and
evaluated in a rat full thickness wound model. The construct con-
tained positioned growth factors and resulted in a reduction in
contraction and an increase in angiogenesis in the early phase of
skin regeneration.
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